Medication info

Irikajung 75 mg (Pregabalin)

Prescription medicationTabletExpired
Ingredient · strength
Pregabalin›75mg / 1 tablet
Manufacturer / importer
Introbiopharma Co., Ltd.
Appearance
White or light yellow round tablet
Packaging
30 tablets/bottle
Approval status
Expired

MFDS item code 201907456 · Approved 2019.10.25

This product's status changed to Expired on 2024.10.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Neuropathic pain; adjunctive treatment of epilepsy (partial seizures); treatment of fibromyalgia
Who uses it
Adults · Children
Adult dosage
This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Although clinical studies have also been conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage according to renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children's dosage
7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12 ~17 years; therefore, use is not recommended.

Ingredients

Manufacturer
Introbiopharma Co., Ltd.

Efficacy & effects

Neuropathic pain; adjunctive treatment of epilepsy (partial seizures); treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive therapy for partial seizures in patients with epilepsy, whether or not accompanied by secondary generalized symptoms. Furthermore, it is effective in the treatment of fibromyalgia. In summary, this drug is used for neuralgia, as an adjunct for partial seizures in epilepsy, and for the treatment of fibromyalgia.

Dosage and Administration

Adult dosage

This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Although clinical studies have also been conducted at a dose of 600 mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage according to renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Administration method Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the administration method. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Children's dosage

7. Pediatric and adolescent patients There are insufficient safety and efficacy data for children under 12 years of age and adolescents aged 12 ~17 years; therefore, use is not recommended.

Precautions

This drug may increase the risk of suicidal thoughts or behavior; therefore, it is crucial to monitor carefully for signs of depression or mood changes during treatment. Patients with hypersensitivity to this medication should not take it. Diabetics should be cautious as weight gain could affect blood sugar control. If symptoms of angioedema occur, the medication should be stopped immediately. Elderly persons should be particularly careful as dizziness or drowsiness may increase the risk of falls. Vision blurring or changes may occur, and symptoms should be reported if they arise. Abruptly stopping this medication may cause withdrawal symptoms such as insomnia, headaches, or anxiety, so it should be tapered off gradually according to doctor's instructions. Patients with a history of drug abuse may be at higher risk for misuse of this medication and should use caution. Patients with reduced renal function may require dose adjustments. Patients with heart disease should consult with a doctor before taking this medication. Caution is advised when taking this drug together with opioid analgesics due to the risk of central nervous system depression. Patients with respiratory or renal disorders may have an increased risk of severe respiratory depression and may require dose adjustments. Pregnant women should avoid this medication during early pregnancy as it may affect the fetus, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping nursing or discontinue the medication as it can be transmitted through breast milk. Activities requiring mental alertness like driving or operating machinery should be avoided until it is clear that this medication does not cause dizziness or drowsiness. Severe skin reactions may occur rarely; if abnormal skin symptoms develop, the medication should be stopped immediately and medical advice sought. In case of an overdose, symptoms may include drowsiness, confusion, or depression; treatment such as hemodialysis may be required if necessary. Keep out of reach of children and be careful not to transfer the medication to another container.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 180 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurry vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • gloom
  • pain
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • reduced oral sensations
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • hives
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensation abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • restlessness
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding the appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsiveness
  • apathy
  • ataxia
  • disturbed motor coordination
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory reduction
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech impairment
  • hypertonic muscle spasm
  • reduced reflexes
  • motor disturbances
  • psychomotor agitation
  • positional dizziness
  • hyperesthesia
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypoactivity
  • olfactory abnormalities
  • taste loss
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • respiratory distress
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • headache
  • loss of consciousness
  • mental disorders
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • seizure
  • shock
  • anaphylactic-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The ideal storage temperature is between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness for an extended period.

Appearance and packaging

Appearance

White or light yellow round tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.